Caduet consists of Amlodipine besylate and atorvastatin calcium. Caduet has a double mechanism of action; action of amlodipin as dihydropyridinic antagonist of calcium and for suppression of atorvastatin HMG-CoA reductase. It is taken for prevention of cardiovascular events at patients with hypertension, with three concurrent factors of cardiovascular risk, with cholesterol level from normal to moderately raised, without clinical manifestations of ischemic heart disease and also when according to the existing recommendations about treatment the combined use of amlodipin and low dose of atorvastatin is deemed appropriate.
Lipitor refers to inhibitors of hydroxymethylglutaryl coenzyme A-reductase. It is used to lower the level of LDL cholesterol (bad cholesterol) in the blood, total cholesterol, triglycerides (another kind of fat) and apolipoprotein B (protein required for cholesterol production). Lipitor is also used to increase the blood cholesterol level of HDL cholesterol (good cholesterol). It is necessary to reduce the risk of hardening of the arteries, which can lead to heart attacks, strokes and peripheral vascular diseases.
A lipid-lowering agent. Reversibly inhibits HMG-COA reductase, inhibits the cholesterol synthesis at the stage of mevinolinic acid and moderately reduces its intracellular concentration. The indications for the drug use include: primary hypercholesterolemia mainly of IIa and IIb types, under the ineffective diet treatment in patients with increased risk of coronary atherosclerosis, hypercholesterolemia combined with hypertriglyceridemia; prevention of coronary artery disease. The drug decreases the risk of myocardial infarction, the need for revascularization of the myocardium, deaths from cardiovascular system diseases.
Zocor is indicated to reduce mortality due to coronary artery disease. It is prescribed for the reduction of risk of serious vascular and coronary complications: non-fatal myocardial infarction, coronary death, stroke; revascularization operations. Designed to reduce the risk of the need for coronary blood flow restoration; rot reduce the risk of the need for surgical intervention to restore peripheral blood flow and other types of non-coronary revascularization; to reduce the risk of hospitalization in connection with attacks of angina pectoris; to decrease in the elevated level of total cholesterol, LDL cholesterol, triglycerides. apolipoprotein B; for increasing HDL cholesterol in patients with primary hypercholesterolemia, including heterozygous familial hypercholesterolemia.
The drug is an inhibitor of the enzyme peptidyl. It inhibits the angiotensin-converting enzyme, which catalyzes the conversion of angiotensin I to vasoconstrictor peptide angiotensin II. Angiotensin II also stimulates the secretion of aldosterone by the adrenal cortex. Inhibition of ACE leads to reduced concentrations of angiotensin II, resulting in low aldosterone secretion. The decrease in the latter leads to an increase in the content of potassium in the blood serum. Since the mechanism is believed to be based on the inhibition of the renin-angiotensin-aldosterone system, it reduces blood pressure even in patients with hypertension with low renin levels.